natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 9, further comprising one or more additional therapeutic agents selected from the group consisting of an inhibitor of HMG-CoA reductase, niacin, a fibrate, 22-hydroxycholesterol, ezetimibe plus simvastatin, a statin with a bile resin, niacin plus a statin, niacin plus an omega-3-fatty acid ethyl ester, a statin, an anti-hANGPTL4 antibody and an anti-PCSK9 antibody. 
Farmaceutski pripravak prema patentnom zahtjevu 9, koji dodatno sadrži jedno ili više dodatnih terapijskih sredstava odabranih iz skupine koja se sastoji od inhibitora HMG-CoA reduktaze, niacina, fibrata, 22hidroksikolesterola, ezetimiba plus simvastatina, statina sa žučnom smolom, nmiacina plus statina, niacina plus etilnog estera omega-3 masne kiseline, statina, anti-hANGPTLA antitijela i anti-PCSKO antitijela.
The anti-CD40 monoclonal antibody or use of any of claims 1-6, wherein said monoclonal antibody binds to said human CD40 antigen with an affinity (KD) of at least about 10-6 M to about 10-12 M. 
Antitijelo za uporabu prema bilo kojem od prethodnih Patentnih zahtjeva, naznačeno time, što se spomenuto antitijelo veže za humani CD40 sa afinitetom (Kn) od najmanje oko 10'6 M ili od najmanje oko 10'8M
Container assembly (300) according to any one of the preceding claims, wherein the cover (2) is adapted to be fluid tightly sealed to the container (1). 
Sklop (300) posude prema Zahtevu 5, gdje pokrivač (2) sadrži zaštitni poklopac za pokrivanje membrane (28).
The compound of claim 9 wherein R1 is phenyl, C1-3alkyl, or trifluoromethyl. 
Spoj prema patentnom zahtjevu 10 pri čemu je R1 fenil ili C1-3alkil.
A solid cosmetic product according to any one of the preceding claims wherein the carbon dioxide effervescent component further comprises a colouring; such as the carbon dioxide effervescent component comprises a water soluble colouring; optionally wherein the carbon dioxide effervescent component comprises colouring in an amount of from 0.001 to 5 wt% based on the carbon dioxide effervescent component. A process for the production of a solid cosmetic product as defined in claims 1 to 14 comprising the steps of: 
HR P20190657 T1 dioksida sadrži sredstvo za bojenje topljivo u vodi; po izboru pri čemu šumeća komponenta ugljikovog dioksida sadrži sredstvo za bojenje u količini od 0.001 do 5 mas. % na osnovi šumeće komponente ugljikovog dioksida. Postupak za proizvodnju čvrstog kozmetičkog proizvoda kako je definiran u patentnim zahtjevima 1 do 14 naznačen time što sadrži korake: i) - pripremanje u vodi dispergirane komponente koja sadrži mast u jednom ili više dijelova i pripremanje šumeće komponente ugljikovog dioksida; i)
The compound of claim 12, wherein the irregular heartbeat disorders and diseases and exercise-induced irregular heartbeat disorders and diseases are selected from the group consisting of atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof 
Spoj prema patentnom zahtjevu 12, naznačen time što su poremećaji i bolesti nepravilnog srčanog rada i poremećaji i bolesti nepravilnog srčanog rada indcirani pojačanom fizičkom aktivnošću izabrani iz grupe koju čine atrijalna 1 ventrikularna aritmija; atrijalna i ventrikularna fibrilacija; atrijalna i ventrikularna tahiaritmija; atrijalna 1 ventrikularna tahikardija; kateholaminergična polimorfna ventrikularna tahikardija (CPVT); i njihove varijante izazvane pojačanom fizičkom aktivnošću.
Fungicidal compositions A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I)
The flask was placed under a nitrogen environment and 350mL (7mUg paclitaxel) anhydrous N,N-dimethyl formamide (DMF) was charged to the flask. The reaction was stirred at room temperature for twenty hours, then was worked up by diluting the reaction solution in 600mL isopropyl acetate (IPAc) and washing with water until the aqueous wash reached pH 7, then with brine. 
Tikvica je bila stavljena u prostor s dušikom 1 u tikvicu je dodano 350 mL (7 mL/g paklitaksela) bezvodnog N,N-dimetil formamida (DMF)., Reakcijska smjesa je bila miješana na sobnoj temperaturi dvadeset sati, tada je bila obrađena razrjedivanjem reakcijske otopine u 600 mL izopropil acetata (IPAc) 1 isprana s vodom sve dok voda od ispiranja ne postigne pH 7, 1 tada sa slanom vodom.
This invention contemplates the antimicrobial composition for use as a medicament for the treatment of festering wounds, trophic ulcers and bums, infiltrations with marked necrotic and exudative components. 
Sastav prema zahtjevu 1, naznačen time, da služi za uporabu kao lijek za liječenje gnojnih rana, trofičkih čireva i opeklina, infiltracija s naznačenim nekrotičkim i eksudativnim komponentama.
The coating formed on the produce from the emulsion has a degree of permeability, thereby enabling the dried coating to readily exchange respiratory products with the surrounding atmosphere. 
Ovojnica koja je formirana na proizvodu iz emulzije posjeduje određeni stupanj propustljivosti, čime je omogućeno da osušena ovojnica lako vrši razmjenu respiratornih proizvoda sa susjednom atmosferom.
The composition according to any one of the preceding claims, which is a solution comprising the or each polypeptide at a concentration in the range of 0.03 to 200 nmol/ml 
Sastav u skladu sa bilo kojim prethodnim zahtjevom, naznačen time, što svaki polipeptid ima koncentraciju u rasponu od 0.03 do 200 nmol/ml, 0.3 do 200 nmol/ml ili 30 do 120 nmol/ml.
The aqueous formulation of any of the foregoing claims comprising one or more excipients selected from a group comprising zinc, m-cresol, glycerol, polysorbate 20 and sodium, preferably comprising 90 µg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/mL glycerol 85% or comprising 90 µg/mLzinc, 2.7 mg/mL m-cresol, 20 µg/mLpolysorbate 20 and 20 mg/mL glycerol 85%. 
Vodena formulacija u skladu s patentnim zahtjevom 6, naznačena time što sadrži 90 mg/ml cinka, 2,7 mg/ml m-krezola i 20 mg/ml 85%-tnog glicerola. Vodena formulacija u skladu s patentnim zahtjevom 6, naznačena time što sadrži 90 mg/ml cinka, 2,7 mg/ml m-krezola, 20 mg/ml polisorbat 20 i 20 mg/ml 85%-tnog glicerola.
In a more preferred embodiment, examples of said glycosylated polypeptide expressed in the transformed microalgae include, but are not limited to, erythropoietin, cytokines such as interferons, antibodies, coagulation factors, hormones, beta-glucocerebrosidase, pentraxin-3, anti-TNFs... 
Metoda u skladu sa patentnim zahtjevom 2, gdje navedeni glikozilirani polipeptid eksprimiran u transformiranoj mikroalgi je eritropoetin, citokin, antitijelo, faktor koagulacije, hormon, beta-glukocerebrozidaza, pentraksin-3, ili anti- TNF.
A pharmaceutical composition of any preceding claim for use as a medicament. A pharmaceutical composition of any preceding claim for use in treating a disease or disorder selected from: metabolic syndrome, macular degeneration, Omega-3 deficiency, cognitive impairment, including as a result of surgery or traumatic brain injury (such as, for example, resulting from a concussion), major depression, suicide, post-partum depression, inflammation, primary sclerosing cholangitis, borderline personality disorder in women, breast cancer, non-alcoholic fatty acid liver disease, and improvement in cognition and behavior in children. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen upotrebi u liječenju bolesti ili poremećaja kojeg se bira između: metaboličkog sindroma, degeneracije makule, nedostatka omega-3 masnih kiselina, kognitivnog poremećaja, uključujući posljedicu kirurškog zahvata ili traumatske ozljede mozga (poput, primjerice, posljedice potresa mozga), velike depresije, samoubojstva, poslijeporođajne depresije, upale, primarnog sklerotizirajućeg kolangitisa, graničnog poremećaja osobnosti kod žena, raka dojke, nealkoholne bolesti masne jetre, te poboljšavanja kognitivnih funkcija i ponašanja kod djece.
The compound for use of any one of claims 8-11, wherein said cancer is selected from the group consisting of breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, leukemia, melanoma, colon cancer, liver cancer, multiple myeloma, renal cell carcinoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, and soft-tissue sarcoma. 
Spoj za primjenu prema bilo kojem od zahtjeva 8-11, naznačen time da se spomenuti karcinom bira iz skupine koju čine karcinom dojke, karcinom jajnika, karcinom prostate, karcinom gušterače, leukemija, melanom, karcinom debelog crijeva, karcinom jetre, multipli mijelom, karcinom bubrežnih stanica, akutna limfocitna leukemija, kronična limfocitna leukemija, akutna akutna mijeloična leukemija 1 sarkom mekog tkiva.
The method of claim 7 further comprising resolving the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a mixture of enantiomers, under suitable conditions to yield a compound of formula (I-S): 
Postupak u skladu s patentnim zahjevom 7, naznačen time što se dodatno sastoji u razdvajanju spoja formule (D, ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-$):
a nucleic acid sequence encoding a polypeptide having a sequence identity of at least 90% to the sequence as depicted in SEQ ID NO:3. 
nukleinskokiselinski slijed koji kodira polipeptid čini slijed najmanje 90 % istovjetan slijedu opisanom u SEQ ID NO:3.
when L1 represents hydrogen, reacting a compound of formula (IV), or a salt thereof, wherein L, L2, L3, L4, R1, m, n, V, W, X, Y and Z are as defined in formula (I), with a compound of formula (III) or a salt thereof in the presence of a reducing agent; or 
kada L1 predstavlja vodik, od reakcije spoja sa formulom (IV), ili njegove soli, [image] gdje su L, L2, L3, L4, R1, m, n, V, W, X, Y i Z kako je definirano u formuli (I), sa spojem sa formulom (III) ili njegovom soli u prisutnosti redukcijskog sredstva; ili
The nucleotides 2′-deoxyadenosine-5′-monophosphate (dAMP) and 2′-deoxyguanosine-5′-monophosphate (dGMP) are both derived de novo from inosine monophosphate (IMP), which in turn is derived from 5-phosphoribosyl-1-pyrophosphate (PPRP). 
Oba nukleotida 2'-deoksiadenozin-5'-monofosfat (LAMP) 1 2'-deoksiguanozin-5'-monofosfat (AGMP) izvode se de novo iz inozin monofosfata (IMP), koji se opet izvodi iz 5-fosforibozil-1-pirofosfata (PPRP).
the non-steroidal anti-inflammatory drug is selected from acetylsalicylic acid, ibuprofen, naproxen, indomethacin, nabumetone, tolmetin, a corticosteroid, prednisone, chloroquine, and hydroxychloroquine; or 
nesteroidni protuupalni lijek se bira između acetilsalicilne kiseline, ibuprofena, naproksena, indometacina, nabumetona, tolmetina, kortikosteroida, prednizona, klorokina i hidroksiklorokina; ili
In particular, the zirconia particles of the present invention are useful for applications where volumetric shrinkage upon curing of the composite material would otherwise be undesirable or even prohibitive. 
To su čestice cirkonijeva oksida iz ovog izuma koje su korisne za primjenu gdje je volumetrijsko skupljanje kompozitnog materijala nakon očvršćivanja nepoželjno ili čak zabranjeno.
The compound or salt of claim 1 or 9, wherein n is 1 and p is 1. 
Spoj ili sol u skladu s patentnim zahtjevom 1 ili 9, naznačen time štojen lipje 1.
said thermochromic ink is coloured below about 38°C and becomes colourless when said temperature is reached or exceeded; 
(b) navedena termokromna tinta je obojana ispod temperature od oko 38*C i postaje bezbojna kada se dosegne navedena temperatura ili kada se ona prijeđe;
As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases. 
Rezultat toga je da su pronašli da su spojevi koje prikazuje sljedeća formula (I) imali željenu aktivnost i bili korisni kao aktivni sastojak lijeka za sprječavanje i/ili terapijsko liječenje gore navedenih bolesti.
In view of this effect the pharmaceutical combinations according to the invention can be used in smaller doses than would be the case with the individual compounds used in monotherapy in the usual way. 
S obzirom na taj učinak, farmaccutske kombinacije sukladno predmctnom izumu mogu sc koristiti u manjim dozama u odnosu na primjenu pojedinačnih spojeva u monoterapiji na uobičajen način.
For example, as shown in FIG. 1 (Scheme 1) and FIG. 2 (Scheme 2), a 9,10-a,a hydroxy taxane F may be formed directly from a standard taxane A or A′ through various transformations, including oxidation of a 10-hydroxy taxane D to a 9,10-diketo taxane E and reduction to the 9,10-a,a-hydroxy taxane F. In the compounds shown in Schemes 1 and 2, R1 and R2 may each be H, alkyl such as an isobutyl group or a tert-butyl group, olefinic such as a tigloyl group, aromatic such as a phenyl group, O-alkyl, O-olefinic, or O-aromatic; R7 may be alkyl such as a methyl group, olefinic or aromatic; and P1 and P2 may each be a hydroxyl protecting group, such as a silyl protecting group, including TBDMS or TES. 
Na primjer, kao što je prikazano na slici 1 (shema 1) 1 na slici 2 (shema 2), 9,10-a,a hidroksi taksan F može biti dobiven direktno iz standardnog taksana A ili A' kroz razne transformacije, uključujući oksidaciju 10-hidroksi taksana D u 9,10-diketo taksan E i redukciju u 9,10-a,a-hidroksi taksan F. U spojevima koji su prikazani na shemama 1 12. R; 1R,, svaki, mogu biti H, alkil kao što je izobutil skupina ili tert-butil skupina, olefin kao što je tigloil skupina, aromatska kao što je fenil skupina, O-alkil, Oolefinska ili O-aromatska; R; može biti alkil, kao što je metil skupina, olefinska ili aromatska skupina; i P, i P» mogu, svaki, biti hidroksil zaštitna skupina, kao što je silil zaštitna skupina, uključujući TBDMS ili TES.
These lozenges are made and deposited at high temperatures (for example 120° C.) and comprise a sodium carbonate buffer. 
Ove tablete su napravljene i čuvaju se na visokim temperaturama (na primjer 120%C) i sadrže natrijev karbonatni pufer.
TLK199, identified in those patents and publications as TER 199, is the diethyl ester of TLK117; while TLK261 and TLK262 are the dimethyl and diisopropyl esters, respectively. 
TLK 199, je dietil ester od TLK 117; dok su TLK 261 1 TLK 262 dimetil i diizopropil esteri, pojedinačno. US objavljena prijava Br.
determining whether less of said complex is formed in the presence of the test compound than in the absence of the test compound; wherein said determination is indicative of the test compound being a GLP-1 secretagogue or a compound useful for preventing or treating a condition ameliorated by increasing a blood GLP-1 level. 
(c) određivanje da li se manje navedenog kompleksa formira u prisutnosti test spoja nego li u odsutnosti test spoja; pri čemu je navedeno određivanje indikativno da je test spoj GLP-1 sekretogog. Uporaba u skladu sa zahtjevom 29, naznačena time, da postupak nadalje obuhvaća korake:
Arginine (R) at heavy chain amino acid position 43; 
(Cc) arginin (R) na aminokiselinskoj poziciji 43 jakog lanca;
The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 19, wherein in the treatment, a muscular dystrophy patient has a mutation to be targeted by exon 45 skipping in the dystrophin gene. The antisense oligomer or pharmaceutically acceptable salt or hydrate thereof according to claim 19 or 20, wherein the patient is a human patient. 
Antisens oligomer ili njegova farmaceutski prihvatljiva sol ili hidrat za uporabu u prema zahtjevu 14, naznačen time što kod liječenja, pacijent s mišićnom distrofijom ima mutaciju koju treba ciljati egzonom 45 preskakanjem gena distrofina, pri čemu je pacijent izborno ljudski pacijent.
a sequence which has at least 70% homology to the sequence of (i) which sequence is capable of tolerising an individual to the sequence of (i), or 
sekvenca koja ima najmanje 70% homologije na sekvencu od (i), te koja je sposobna na toleranciju pojedinca na sekvencu od (i), ili
Purification by automated flash chromatography (gradient elution: EtOAc/DCM 0-50%) provides the title compound as a pale yellow solid. 
Čišćenjem pomoću automatizirane vakuumske kromatografije (gradijent ispiranja: ECOAc/DCM 0-50%) dobije se naslovni spoj kao blijedo žuta kruta tvar.
This is especially advantageous since the biasing force of the closing mechanism when being in its closed position can be adapted to the needs of a user of the device. 
Uređaj u skladu s patentnim zahtjevom 3 ili 4, naznačen time što se ekscentrična osovina (13) koljenaste osovine mehanizma za zatvaranje (1) može okretati.
A compound according to any one of claims 1 to 10 for use in the treatment or prevention of a condition or disorder selected from the group consisting of obesity, diabetes, anorexia nervosa, bulimia, cachexia, syndrome X, insulin resistance, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, nonalcoholic fatty liver disease, atherosclerosis, arteriosclerosis, acute heart failure, congestive heart failure, coronary artery disease, cardiomyopathy, myocardial infarction, angina pectoris, hypertension, hypotension, stroke, ischemia, ischemic reperfusion injury, aneurysm, restenosis, vascular stenosis, skin cancer, melanoma, lymphoma, breast cancer, lung cancer, colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, prostate cancer, kidney cancer, liver cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer, ovarian cancer, and acne vulgaris. 
agonisti receptora peroksiznih proliferativnih aktivatora. Spoj prema bilo kojem zahtjevu 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se koristi kao lijek. Spoj prema bilo kojem zahtjevu 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se koristi u liječenju pretilosti, dijabetesa, bulimije, sindroma X, inzulinske rezistencije, hipoglikemije, hiperglikemije, hiperurikemije, hiperinzulinemije, hiperkolesterolemije, hiperlipidemije, dislipidemije, miješane dislipidemije, hipertrigliceridemije, pankreatitisa i ne-alkoholne bolesti masne jetre, ateroskleroze, arterioskleroze, akutne srčane isuficijencije, kongestivne srčane isuficijencije, koronarne arterijske bolesti, kardiomiopatije, miokardijskog infarkta, angine pektoris, hipertenzije, hipotenzije, udara, ishemije, ishemijske reperfuzijske ozljede, aneurizma, restenoze i vaskularne stenoze.
The method according to any of the preceding claims, further comprising the step of receiving a scrambled image, wherein said received scrambled image is stored in an allocated memory (42), said received scrambled image is expanded into a character string, said character string is decrypted, and the decrypted character string is converted to an image of a document. 
Postupak prema bilo kojem prethodnom zahitjevu, naznačen time, da nadalje obuhvaća korak zaprimanja ispremetane slike, gdje je spomenuta zaprimljena ispremetana slika spremljena u dodijeljenu memoriju (42), dok je spomenuta zaprimljena ispremetana slika rastegnuta u povezani niz znakova, pri čemu spomenuti niz znakova je dešifriran, te je dešifrirani niz znakova pretvoren u sliku dokumenta.
A humanized antibody specific for the protofibrillar form of the A-B peptide, wherein said antibody comprises as heavy chain comprising SEQ ID NO:26 and a light chain comprising SEQ ID NO:22. 
teški lanac koji obuhvaća polipeptidnu sekvencu SEQ ID NO: 26 i laki lanac koji obuhvaća polipeptidnu sekvencu SEQ ID NO: 22. HR P20181985 T1
In specific embodiments, the metallic nanoparticle or metallic nanoshell is selected from the group consisting of gold particles, silver particles, copper particles, platinum particles, cadmium particles, composite particles, gold hollow spheres, gold-coated silica nanoshells, and silica-coated gold shells. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se metalnu nanočesticu ili metalnu nanoljusku bira iz skupine koju čine čestice zlata, čestice srebra, čestice bakra, čestice platine, čestice kadmija, kompozitne čestice, šuplje kuglice od zlata, nanoljuske od silicijevog dioksida obložene zlatom, te zlatne ljuske obložene silicijevim dioksidom.
The pharmaceutical composition according to claim 1, wherein the prilocaine HCl content is 2% (w/V). 
Farmaceutska kompozicija prema patentnom zahtjevu 1 ili 2, naznačena time što je sadržaj prilokaina HCI 2% (tež./vol.).
granulating the materials from step (2) using a dry granulation process comprising: 
granuliranja materijala iz koraka (3) korištenjem procesa suhe granulacije, gdje process suhe granulacije obuhvaća:
The conjugated nucleic acid molecule according to claim 2, wherein the molecule is and wherein the underlined nucleotide refers to a nucleotide having a phosphorothioate backbone. 
CGACACGGGTGTTGGGTCGTITGITOGGATOT g AJ te što se podcrtani nukleotid odnosi na nukleotid s fosforotioatnom okosnicom.
The rodent of claim 1, wherein the rodent does not express a1, a2, and a3 domains of an endogenous rodent MHC I polypeptide from an endogenous rodent MHC I locus. 
Nukleinska kiselina prema zahtjevu 1, naznačena time, da ne-ljudski MHC-I-polipeptid je MHC-I-polipeptid glodavca, te time, da druga sekvenca nukleinske kiseline kodira transmembranske i citoplazmatske domene MHCI-polipeptida glodavca.
The form of the triangle-like carrier body 20 corresponds to the triangle 35 formed by the three engage members 14, 15, 16 and both triangles are oriented the same way. 
Prijenosni uređaj prema zahtjevu 9., naznačen time da oblik trokuta tijela (20) nosača odgovara trokutu kojeg čine zahvatni članovi (14, 15, 16).
a second tank disposed below the nozzle unit and containing a calcium chloride solution, wherein the distance between the surface of the calcium chloride solution in the second tank and the liquid outlet of the nozzle unit ranges from 0.1 m to 1.5 m. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što je drugi spremnik tako smješten ispod mlaznične jedinice da se udaljenost između površine otopine kalcijevog klorida i izlaza za tekućinu mlaznice kreće od 0,1 m do 1,5 m.
mixing said carrier, said long-acting B2-agonist, and, optionally, said inhaled corticosteroid in a vessel of a shaker mixer at a speed of rotation of 16 to 32 rpm for a time of 60 to 120 minutes, to obtain a first mixture; and 
miješanje rečenog nosača, rečenog dugodjelujućeg B2-agonista, te, opcionalno, rečenog kortikosteroida za inhalaciju u posudi miješalice s potresivanjem pri brzini rotacije ne manjoj od 16 r.p.m. u vremenu ne kraćem od 60 minuta, da se dobije prva smjesa; te
The active compounds in the combination, i.e. the M3 antagonist of the invention, the corticosteroid and any other optional active compounds may be administered by any suitable route, depending on the nature of the disorder to be treated, e.g. orally (as syrups, tablets, capsules, lozenges, controlled-release preparations, fast-dissolving preparations, lozenges, etc); topically (as creams, ointments, lotions, nasal sprays or aerosols, etc); by injection (subcutaneous, intradermic, intramuscular, intravenous, etc.) or by inhalation (as a dry powder, a solution, a dispersion, etc). 
Djelatni spojevi u kombinacijama, tj. M3 antagonist sukladno predmetnom izumu, f2-agonist 1 svi drugi izborni djelatni spojevi mogu se davati bilo kojom prikladnom rutom, ovisno o prirodi bolesti koja se liječi, npr. peroralno (u obliku sirupa, tableta, kapsula, pastila, pripravaka s nadziranim otpuštanjem, pripravaka s brzim otapanjem, pastila itd.); lokalno (u obliku krema, pomada, losiona, nazalnih sprejeva ili aerosola, itd.); uštrcavanjem (subkutano, intradermalno, intramuskularno, intravenski, itd.) ili inhalacijom (u obliku suhog praška, otopine, disperzije, itd.).
The compositions have the form of a tablet comprising 
FARMACEUTSKI SASTAV KOJI OBUHVAĆA PANTOPRAZOL U OBLIKU GRANULA